The code block below illustrates how one might use # and // as comments in your logic and calculations.

This value you provided is not a number. Please try again.

This value you provided is not an integer. Please try again.

The value entered is not a valid Vanderbilt Medical Record Number (i.e. 4- to 9-digit number, excluding leading zeros). Please try again.

The value you provided must be within the suggested range

The value you provided is outside the suggested range

This value is admissible, but you may wish to double check it.

The value entered must be a time value in the following format HH:MM within the range 00:00-23:59 (e.g., 04:32 or 23:19).

This field must be a 5 or 9 digit U.S. ZIP Code (like 94043). Please re-enter it now.

This field must be a 10 digit U.S. phone number (like 415 555 1212). Please re-enter it now.

This field must be a valid email address (like joe@user.com). Please re-enter it now.

The value you provided could not be validated because it does not follow the expected format. Please try again.

Required format:

r9928KQ2Qdphcq44yDVQMWMgzQLVzGabLSx5iPxuxZnooTKysQvS6svCvJtXZYn52Hg9jqUhj87S

COVID-19 Monoclonal Antibody Therapy Clinical Decision Tool

Since a November 2020 Federal Drug Administration Emergency Use Authorization (EUA), patients who test positive for COVID-19, have mild to moderate disease and are at risk for progression to severe disease have been eligible to receive a single intravenous (or subcutaneous) dose of therapeutic monoclonal antibodies (mAbs) against SARS CoV-2. Patients who are admitted to the hospital for reasons other than COVID-19, and who have mild-moderate COVID-19, may also receive these therapies. Just as human insulin is produced in large quantities in a laboratory, therapeutic monoclonal antibodies against SARS CoV-2 are produced by pharmaceutical companies. The products are effective with a low side-effect profile. Their approval was based on analyses of outpatient randomized controlled trials, which showed a reduction in COVID-19 related hospitalization or emergency room visits with their use. On July 30, 2021, the EUA was updated to add an indication for post-exposure prophylaxis of COVID-19 in certain individuals who are at high risk for progression to severe COVID-19. Post-exposure prophylaxis with REGEN-COV is not a substitute for vaccination against COVID-19. REGEN-COV is not authorized for pre-exposure prophylaxis for prevention of COVID-19.

***** Use of mAb therapy is based on evidence that supports your clinical judgment. The point here is not to exclude anyone from getting the product if you, the provider, make a clinical decision to utilize it in an individual. This is a tool to help remind you of the broad range of criteria that makes patients 12 years of age and older eligible for this therapy. *****

Does your patient have a positive PCR test or antigen test AND the diagnosis of COVID-19?

* must provide value

Yes No

reset

Did your patient's symptoms start within the last 10 days?

* must provide value

Yes No

reset

Is your patient symptomatic but not yet progressed to require hospitalization or oxygen therapy (or increase from baseline home oxygen therapy)?

* must provide value

Yes No

reset

Has your patient been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Centers for Disease Control and Prevention (CDC)?

Close contact is anyone who was within 6 feet of an infected person for a total of 15 minutes or more.

* must provide value

Yes No

reset

Is your patient >40 Kg AND at least 12 years old?

* must provide value

Yes No

reset

Is your patient not fully vaccinated or not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications)?

* must provide value

Yes No

reset

Which of the following risk factors puts your patient at high risk for progression to severe disease?

* must provide value

Older age (greater or equal to 65 years)

Cardiovascular disease (including congenital heart disease) or hypertension

Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis, and pulmonary hypertension)

BMI greater than or equal to 25 kg/m2 (overweight or obese)

Age 12-17 years of age weighing at least 40 kg with BMI ≥85th percentile for their age and gender based on CDC growth charts

Chronic kidney disease

Diabetes mellitus

Pregnancy

Immunosuppressive disease and/or immunosuppressive treatments

Sickle cell disease

Neurodevelopmental disorder (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)

Medical related technological dependence such as tracheostomy, gastrostomy, positive pressure ventilation

Other medical conditions or factors (for example race or ethnicity) that may place individual patients who are >12 years of age at high risk for progression to severe disease. Use of mAb therapy is based on evidence that supports your clinical judgment.

Based on the answer(s) provided, your patient is ineligible for mAb therapy.

Please view the interactive map below and press SUBMIT once you have located the COVID-19 Monoclonal Antibody Treatment Site that best fits your patient's needs.

You have selected an option that triggers this survey to end right now.

To save your responses and end the survey, click the 'End Survey' button below. If you have selected the wrong option by accident and/or wish to return to the survey, click the 'Return and Edit Response' button.